The United States Patent and Trademark Office (USPTO) has issued patent US12584906B2, titled 'Coating agent for inducing differentiation of pluripotent stem cells into brain microvascular endothelium-like cells and use thereof.' The patent, assigned to Public University Corporation Nagoya City University, covers a specific coating agent containing a Laminin-221 fragment or an N-terminal Vitronectin. This technology is intended to enable the stable differentiation of pluripotent stem cells into brain microvascular endothelium-like cells, a critical step for research into neurological conditions and potential cell-based therapies.

This patent grant does not impose new regulatory obligations on regulated entities. However, it signifies intellectual property protection for a novel technology in the stem cell and biotechnology field. Companies involved in stem cell research, drug development, or regenerative medicine, particularly those working with endothelial cells or neurological applications, should be aware of this patent. While not a direct compliance requirement, understanding existing patents is crucial for avoiding infringement and for strategic R&D planning.